Allos reports Phase II data

ALTH said data from 44 evaluable patients in a Phase II trial of its RSR13 radioenhancement agent showed an overall response rate of 89% in the chest, with 80% partial responses and 9% complete responses. ALTH also said the estimated 1- and 2-year survival rates were 65% and 51%, respectively. In addition, ALTH said median survival had not been reached, with a 1-year progression-free rate of 55% and a 2-year rate of 21%. ...